Shots:

• The P-III study involves assessing of spartalizumab (PDR001) + Tafinlar (dabrafenib) and Mekinist (trametinib) vs PBO + Tafinlar and Mekinist in previously untreated patients with unresectable or metastatic BRAF V600 mutation-positive melanoma
• The study was conducted in three parts while today’s results are from part 3 of the trial. The study did not meet its 1EPS of investigator-assessed progression-free survival
• Spartalizumab is mAb targeting PD-1 receptor while Tafinlar and Mekinist are prescription medicines- used in combination to prevent melanoma

­ Ref: Novartis | Image: Novartis